These compound inhibitors were shown to inhibit galectin-3 binding to its ligands and inhibit galectin-3-mediated cancer cell adhesion, invasion, angiogenesis, as well as inhibit macrophage secretion of pre-inflammatory cytokines. The gene discussed is LGALS3; the disease is cancer.